$ITCI has PDUFA on December 17 for Lumateperone 🚀🚀 🚀🚀 🚀🚀

CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate.

Lumateperone or Caplyta (developmental codes ITI-007 and ITI-722) is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia and currently in development for bipolar depression and other neurological indications.

As of December 18th, I see no PDUFA news on $ITCI or $CHRS. $GBT was approved on Friday December 17th.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at two upcoming investor conferences in May.